

# Adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) is a fine-tune regulator of the collagen1:collagen3 balance

Miguel Perez-Aso · Aránzazu Mediero ·  
Bruce N. Cronstein

Received: 2 April 2013 / Accepted: 15 May 2013 / Published online: 8 June 2013  
© Springer Science+Business Media Dordrecht 2013

**Abstract** Adenosine is a potent endogenous anti-inflammatory and immunosuppressive metabolite that is a potent modulator of tissue repair. However, the adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R)-mediated promotion of collagen synthesis is detrimental in settings such as scarring and scleroderma. The signaling cascade from A<sub>2A</sub>R stimulation to increased collagen production is complex and obscure, not least because cAMP and its downstream molecules PKA and Epac1 have been reported to inhibit collagen production. We therefore examined A<sub>2A</sub>R-stimulated signaling for collagen production by normal human dermal fibroblasts (NHDF). Collagen1 (Col1) and collagen3 (Col3) content after A<sub>2A</sub>R activation by CGS21680 was studied by western blotting. Contribution of PKA and Epac was analyzed by the PKA inhibitor PKI and by knockdowns of the PKA-C $\alpha$ , -C $\beta$ , -C $\gamma$ , Epac1, and Epac2. CGS21680 stimulates Col1 expression at significantly lower concentrations than those required to stimulate Col3 expression. A<sub>2A</sub>R stimulates Col1 expression by a PKA-dependent mechanism since PKA inhibition or PKA-C $\alpha$  and -C $\beta$  knockdown prevents A<sub>2A</sub>R-mediated Col1 increase. In contrast, A<sub>2A</sub>R represses Col3 via PKA but stimulates both Col1 and Col3 via an Epac2-dependent mechanism. A<sub>2A</sub>R stimulation with CGS21680 at 0.1  $\mu$ M increased Col3 expression only upon PKA blockade. A<sub>2A</sub>R activation downstream signaling for Col1 and Col3 expression proceeds via two distinct pathways with varying sensitivity to cAMP activation; more highly cAMP-sensitive PKA activation stimulates Col1 expression, and less cAMP-sensitive Epac activation promotes both Col1 and Col3 expression. These observations may explain the dramatic change

in Col1:Col3 ratio in hypertrophic and immature scars, where adenosine is present in higher concentrations than in normal skin.

**Keywords** Adenosine · Adenosine receptor A<sub>2</sub> · Collagen type I · Collagen type III · PKA · Epac

## Abbreviations

Col1	Collagen type I
Col3	Collagen type III
A <sub>2A</sub> R	Adenosine A <sub>2</sub> receptor
NHDF	Normal human dermal fibroblasts

## Introduction

Adenosine, a product of ATP catabolism [1], is present in most biological fluids and is elevated during tissue or organ stress when it acts as a potent endogenous modulator of inflammation and tissue repair [2, 3]. Under basal conditions, the extracellular adenosine concentration is constant (30–300 nM). In contrast, its concentration increases dramatically to micromolar ranges when there is increased ATP catabolism, as in tissue or cellular necrosis and hypoxia [4]. It has been previously reported that adenosine, acting via adenosine 2A receptor (A<sub>2A</sub>R), promotes wound healing [5] and excisional wound closure in both normal and diabetic mice, and the enhancement in dermal wound healing is accompanied by an increase in matrix (collagen) in the wounds [6, 7]. In addition, the A<sub>2A</sub>R plays an important role in the pathogenesis of fibrotic malignancies of the skin such as dermal fibrosis and scleroderma [8–10] and liver [11]. Thus, blockade or deletion of adenosine A<sub>2A</sub>R prevents dermal fibrosis in mice treated with bleomycin [12], and A<sub>2A</sub>R blockade prevents scarring by reducing collagen content and misalignment [10]. Similarly, deletion or blockade of adenosine A<sub>2A</sub>R prevents liver fibrosis in mice treated with CCl<sub>4</sub> or thioacetamide [11]. Adenosine

**Electronic supplementary material** The online version of this article (doi:10.1007/s11302-013-9368-1) contains supplementary material, which is available to authorized users.

M. Perez-Aso (✉) · A. Mediero · B. N. Cronstein  
Division of Translational Medicine, Department of Medicine, New York University School of Medicine, 550 First Avenue, MSB 255, New York, NY 10016, USA  
e-mail: miguel.perezaso@nyumc.org

$A_{2A}R$  ligation directly stimulates collagen production by stimulated dermal fibroblasts [13, 14] and stellate cells [15].

The  $A_{2A}R$  belongs to the G-protein-coupled receptor (GPCR) superfamily [16, 17] and signals via  $G_s$  signal transduction proteins which activate adenylate cyclase, increasing cytosolic cAMP [18]. Elevated intracellular cAMP activates both protein kinase A (PKA) and Epac [19–21]. Because the  $A_{2A}R$  is the only  $G_s$ -coupled adenosine receptor subtype which has not been reported to also couple to the  $G_q$  protein [22, 23], it is likely that  $A_{2A}R$ -mediated increases in collagen expression are related to either PKA or Epac activation by cAMP. However, a prior study suggests that both PKA and Epac activation diminish collagen1 (Col1) and collagen3 (Col3) expression [24]. In support of the hypothesis that cAMP diminishes collagen production, the profibrogenic agonist transforming growth factor  $\beta$  (TGF $\beta$ ) decreased Epac1, but not Epac2, expression in fibroblasts from multiple tissues and stimulated Col1 and Col3 expression; activation of both Epac1 and PKA inhibited Col1 and Col3 expression [25]. Moreover, targeting an increase in cAMP has been proposed as an antifibrotic strategy [24]. Since the adenosine  $A_{2A}R$  is a  $G_s$ -coupled receptor that stimulates an increase in cAMP in nearly every cell tested, the mechanism by which  $A_{2A}R$  regulates collagen production remains a paradox.

There is a marked decrease in the ratio of Col1 to Col3 in the matrix of scars or in the fibrous matrix of cirrhotic liver as compared to normal tissues, and blockade of adenosine  $A_{2A}R$  appears to affect Col3 more than Col1 expression in scars [10]. In scars, matrix composition dictates both the strength and the appearance of the resulting scar so it is important to understand how agents that may alter the wound healing or scarring process regulate the composition of the wound matrix. Interestingly, the intracellular signaling pathways by which adenosine  $A_{2A}R$ s signal for expression of Col1 and Col3 differ in hepatic stellate cells;  $A_{2A}R$  stimulation promotes an increase in Col1 expression via the PKA/ERK pathway but increases Col3 expression via a pathway involving activation of p38MAPK in the LX-2 hepatic stellate cell line [15]. We therefore asked how activation of  $A_{2A}R$  promotes an increase of both Col1 and Col3 favoring dermal fibrosis and scarring. Here we report that  $A_{2A}R$ s differentially regulate Col1 and Col3 expression via a complex mechanism dependent on cAMP but proceeding via either PKA- or Epac-dependent signaling pathways.

## Results

The dose–response relationship for  $A_{2A}R$ -stimulated increases in Col1 and Col3 differ


To better define the effects of  $A_{2A}R$ -mediated stimulation on synthesis of wound matrix by dermal fibroblasts, we

examined the dose–response relationship for the selective  $A_{2A}R$  agonist CGS21680-mediated stimulation of collagen1 (Col1) and collagen3 (Col3) by normal human dermal fibroblasts (NHDF). Since the well-known profibrotic peptide TGF- $\beta$ 1 increased both Col1 and Col3 after 24 h (Supplemental Figure 1), NHDF were also incubated with CGS21680 for 24 h. We were surprised to find that the concentrations of CGS21680 required to stimulate increased production of Col1 (both components:  $1\alpha 1$  and  $1\alpha 2$ ) and Col3 differed markedly, even though stimulation was mediated by the  $A_{2A}$  receptor since SCH58261, a highly selective  $A_{2A}R$  antagonist, reverses the effect of CGS21680 on both collagens (Fig. 1). Moreover, when we analyzed the ratio of Col1:Col3 expression in NHDF stimulated with CGS21680, we found that the ratio of Col1:Col3 production decreased significantly from  $4.2\pm 0.5$  to  $2.9\pm 0.3$  as the concentration of CGS21680 increased from 0.1 to 10  $\mu$ M. The change in Col1:Col3 ratio at differing  $A_{2A}R$  agonist concentrations is likely to be physiologically and pharmacologically important since, in normal skin, where adenosine concentration varies from 30 to 300 nM, there is a Col1 to Col3 ratio of 4:1, but in hypertrophic and immature scars, where adenosine concentration is at micromolar ranges, the ratio decreases to 2:1 [4]. That  $A_{2A}R$  activation increases Col1 and Col3 expression was further corroborated by quantitation of mRNA for these proteins (Fig. 1c); these results were in agreement with previously published results obtained in studies of hepatic stellate cells and the human hepatic stellate cell line LX-2 [15].

### PKA activates Col1, but inhibits Col3 production after $A_{2A}R$ activation

Adenosine receptors are all members of the large family of G-protein-coupled receptors, and the  $A_{2A}R$  signals almost exclusively via  $G_{\alpha s}$  signal transduction proteins, which activate adenylate cyclase and mediate downstream signaling via cAMP, which leads to activation of two divergent pathways activated by protein kinase A (PKA) and the guanine nucleotide exchange factor Epac1/2. As expected,  $A_{2A}R$  activation by the specific agonist CGS21680 increased the intracellular levels of cAMP in a dose-dependent fashion (Fig. 2a). To follow, we studied the impact of PKA inhibition on the CGS21680 activation of Col1 and Col3. The PKA inhibitor, PKI, dramatically decreased PKA activity ( $95.83\pm 4.16$  % inhibition,  $P<0.01$  Student's *t* test; Fig. 2b) and completely blocked the effect of adenosine  $A_{2A}R$  stimulation by CGS21680 on Col1 expression (Fig. 2c). In contrast, PKI alone enhanced the effect of CGS21680 0.1  $\mu$ M on Col3 expression ( $170.2\pm 18.1$  % of control,  $P<0.001$  Student's *t* test).

Since three different PKA catalytic subunits have been discovered [26], we next silenced PKA-C $\alpha$ , PKA-C $\beta$ , and PKA-C $\gamma$  (Fig. 3a) which, interestingly, increased basal Col1



**Fig. 1** A<sub>2A</sub>R activation increase collagen I and III with different potency. **a** NHDF cells were incubated with increasing concentrations of the A<sub>2A</sub>R agonist CGS21680 during 24 h, with or without pre-incubation with the A<sub>2A</sub>R selective antagonist SCH58261 0.1 μM. *Black triangle* represents the increasing concentrations of CGS21680 0.1–1–10 μM. **b** Densitometry of bands showing percent change and Col1:Col3 ratio. Data represent means±SEM of more than ten independent experiments, and statistics was performed by ANOVA

followed by Newman–Keuls post-test, Col1 **\*\****P*<0.01 and Col3 **##***P*<0.01 vs. non-stimulated control; **\****P*<0.05 CGS21680 0.1 vs. 10 μM; or by two-way ANOVA, **&&&***P*<0.001 and **&&***P*<0.01 SCH58261 vs. control. **c** mRNA for collagen1α1 and collagen3α1 was measured by real-time RT-PCR after a 24-h stimulation with CGS21680 1 μM. Data represent means±SEM of four independent experiments, and statistical analysis was performed by Student's *t* test, collagen1α1 **\*\*\****P*<0.001 and collagen3α1 **##***P*<0.01 vs. non-stimulated control

and Col3 expression. Col1 expression was unaffected by CGS21680 treatment in PKA-C $\alpha$  and PKA-C $\beta$  knockdown cells, but it was markedly increased by CGS21680 in PKA-C $\gamma$ -depleted cells. Col3 expression after A<sub>2A</sub>R activation was increased when compared to basal expression in all three knockdowns, although the difference was not significant in PKA-C $\beta$ -depleted cells (Fig. 3b).

Epac2 is required for Col1 and Col3 production following A<sub>2A</sub>R activation

Prior studies indicate that Epac plays a significant role in regulating collagen synthesis and fibroblast migration, suggesting that Epac1 is a negative regulator of both Col1 and Col3 [25]. Therefore, we also investigated the impact of Epac on Col1 and Col3 production after A<sub>2A</sub>R activation by CGS21680, which robustly increased Epac activity (Fig. 4a). Next, we silenced Epac1 or Epac2 (Fig. 4b). Interestingly, Epac1 silencing increased basal expression of both Col1 and Col3 (Col1 142.2±19 %,  $P<0.05$  vs. negative control; Col3 150.4±10 %,  $P<0.001$  vs. negative control), and levels were also elevated upon increasing concentrations of CGS21680. However, Epac2 depletion prevented the CGS21680-induced increase in both Col1 and Col3 (two-way ANOVA,  $P<0.001$ ), and double knockdown of Epac1/2 prevented Col3 but not Col1 increase after A<sub>2A</sub>R activation (Fig. 4c). These results confirm previous reports in which Epac1 was found to negatively regulate Col1 and Col3 [25] and suggest that Epac2 is required for the expression of Col1 and Col3 following adenosine A<sub>2A</sub>R stimulation.


## Discussion

Collagen is the principal building block of connective tissue, and its upregulation in malignancies such as scleroderma is a critical event in the development of tissue fibrosis [27]. In normal skin, types I and III collagen exist in a ratio approximately 4:1, whereas in hypertrophic and immature scars, the percentage of type III collagen may be as high as 33 %, altering the ratio of Col1 to Col3 to as low as 2:1 [4]. Adenosine is present in most biological fluids and is elevated during tissue stress when it acts as a potent endogenous modulator of inflammation and tissue repair [2, 3] so that physiological interstitial levels of adenosine of 30 to 300 nM are found in normal tissues, while adenosine concentrations can reach micromolar levels during hypoxia, ischemia, inflammation, and other types of injury [28]. We therefore sought to analyze the impact of the A<sub>2A</sub>R agonist CGS21680 ranging from nanomolar to micromolar concentrations. It has previously been reported that adenosine, acting via the A<sub>2A</sub>R, promotes an increase in collagen in

wounds [6, 7] and in vitro [12, 14]. In fact, we have previously shown that A<sub>2A</sub>R stimulation promotes dermal fibrosis, as both A<sub>2A</sub>R antagonism and knockdown protect mice from developing bleomycin-induced dermal fibrosis and A<sub>2A</sub>R antagonism prevents excessive scarring by hampering Col3 overproduction compared to Col1 [10] and protects from dermal fibrosis in a model of elevated tissue adenosine [29]. We therefore hypothesized that Col1 production is more sensitive to A<sub>2A</sub>R activation than Col3 so that increasing concentrations of CGS21680 would decrease the Col1:Col3 ratio. Interestingly, hypoxia increases adenosine extracellular levels by suppressing both adenosine uptake and metabolism [30–33] and, at the same time, conditions of hypoxia promote fibrogenesis [34]. Moreover, HIF-1 $\alpha$  induces A<sub>2B</sub>R expression [35] indicating that the A<sub>2B</sub>R exerts a tissue protective function [36, 37], but the A<sub>2A</sub>R may also contribute to the functions of adenosine in ischemic settings [35, 36]. Therefore, further studies will be needed to fully understand the interplay between hypoxia, HIF-1 $\alpha$ , and adenosine in skin fibrosis. In this regard, and highlighting the hypoxia–inflammation relationship [30], it has been recently shown that hypoxia elicits a potent anti-inflammatory mechanism to limit tissue damage in conditions of reduced oxygen availability [38].


Among the most well-known effects of adenosine A<sub>2A</sub>R receptor stimulation is increasing intracellular cAMP [28, 39, 40], and A<sub>2A</sub>R stimulation activates both PKA [20] and Epac [19]. Moreover, the A<sub>2A</sub>R has been shown not to couple to the Gq/PLC/PKC pathway [22, 28]. In fact, direct activation of PKC with phorbol 12-myristate 13-acetate (PMA) dramatically inhibits both Col1 and Col3 (Supplemental Figure 2), strongly indicating that A<sub>2A</sub>R promotion of collagen signals via cAMP. Paradoxically, both Epac and PKA have been reported to decrease Col1 and Col3 synthesis in human fibroblasts [25], and others have suggested that stimulating increased cAMP levels or activating Epac could be used to inhibit fibrosis [24]. Thus, Yokoyama et al. showed that mRNA expression of both Col1 and Col3 is decreased by activation of both enzymes PKA and Epac using cAMP analogs that specifically activate PKA or Epac at 50  $\mu$ M [25]. The work reported here clearly confirms the role of cAMP/PKA/Epac activation in adenosine A<sub>2A</sub>R-mediated stimulation of collagen production, which is in agreement with the finding that collagen is increased by activation of other adenylyl cyclase-coupled receptors such as the angiotensin AT-1R [41].

Previous reports suggest that differences in cAMP affinities between PKA isoforms contribute to specificity in the cAMP pathway [42, 43], and our results are consistent with this hypothesis. Moreover, inhibition of PKA by PKI dramatically reduced PKA activity (Fig. 2b) and prevented A<sub>2A</sub>R-mediated stimulation of Col1 expression but potentiated Col3 expression. In agreement with previous findings,



**Fig. 2** PKA activates collagen I but inhibits collagen III. **a** Intracellular cAMP levels were measured as described in “Methods” section. Statistical analysis was performed by Student’s *t* test, \*\*\**P* < 0.001 vs. non-stimulated. **b** PKA activity measurement; when indicated, 1 h prior to CGS21680 stimulation, NHDF were pre-incubated with the PKA inhibitor PKI (10  $\mu\text{g}/\text{ml}$ ), and PKA activity was analyzed as

described in “Methods” section. **c** Cells were pre-incubated with the PKA inhibitor PKI (10  $\mu\text{g}/\text{ml}$ ) before CGS21680 addition and Col1 and Col3 expression analysis. *Black triangle* represents the increasing concentrations of CGS21680 0.1–10  $\mu\text{M}$ . Statistical analysis was performed by two-way ANOVA, \*\**P* < 0.01 PKI vs. control. Data represent means  $\pm$  SEM of three or more independent experiments



**Fig. 3** Impact of knockdown of the PKA catalytic subunits on Col1 and Col3 expression. **a** siRNAs for PKA-C $\alpha$ , PKA-C $\beta$ , and PKA-C $\gamma$  selectively reduce the protein expression when compared to control siRNA. **b** Impact of PKA-C $\alpha$ , PKA-C $\beta$ , and PKA-C $\gamma$  silencing on basal and CGS21680 1- $\mu$ M-increased Col1 and Col3 expression.


Statistics was performed by Student's *t* test, \* $P$ <0.05, \*\* $P$ <0.01, and \*\*\* $P$ <0.001 vs. non-stimulated control siRNA and # $P$ <0.01 CGS21680 vs. non-stimulated of the same siRNA. Data represent means $\pm$ SEM of three or more independent experiments

knockdown of the PKA catalytic subunits increased basal Col1 and Col3 expression (Fig. 3b) [25]. To our knowledge, the present work is the first description of a differential regulation of Col1 and Col3 by PKA following A<sub>2A</sub>R activation: we found that the increase in Col1 following CGS21680 incubation was prevented in PKA-C $\alpha$  and -C $\beta$ -depleted cells and that, similar to the impact of the PKI inhibitor, Col3 was further increased by A<sub>2A</sub>R by knockdown of the catalytic subunits of PKA. These results are most consistent with the hypothesis that activation of PKA after A<sub>2A</sub>R activation stimulates Col1 expression but inhibits Col3 expression.

Although PKA was initially thought to be the exclusive mediator of cAMP action [44], it was subsequently

recognized that Epac mediates many of the effects of cAMP on cellular function [45]. To determine whether Epac signaling mediates collagen expression in response to adenosine A<sub>2A</sub> stimulation, we knocked down both Epac1 and 2 (Fig. 4b) and found that Epac1, but not Epac2, silencing increased basal Col1 and Col3 expression (Fig. 4c), which is consistent with the observation that TGF- $\beta$ 1 promotes collagen synthesis by repressing Epac1 but not Epac2 in fibroblasts from different tissues [25]. Interestingly, the effect of A<sub>2A</sub>R stimulation on both Col1 and Col3 expression was lost in Epac2-silenced cells. These findings suggest that after A<sub>2A</sub>R activation, Epac2 is necessary for Col1 and Col3 expression, and its regulation by G<sub>s</sub> linked receptors.

**Fig. 4** Impact of Epac1/2 knockdown on Col1 and Col3 expression. **a** Epac activity was analyzed after incubation with CGS21680 1  $\mu$ M for 15 min. Immunoprecipitation with Ral GSD-RBD was performed followed by immunoblot with anti-Rap1, and Coomassie stain identified Ral GSD-RBD at the predicted molecular weight of 37 kDa. **b** siRNAs for Epac1, Epac2, and double knockdown Epac1+2 selectively reduce the protein expression when compared to control siRNA. **c** Impact of Epac1, Epac2 silencing, or double knockdown Epac1+2 on basal and CGS21680-increased Col1 and Col3 expression. Statistics was performed by the two-way ANOVA: Epac2 siRNA \*\*\* $P$  < 0.001 and Epac1+2 siRNA ## $P$  < 0.01 vs. control siRNA. *Black triangle* represents the increasing concentrations of CGS21680 0.1–10  $\mu$ M, and data represent means  $\pm$  SEM of three or more independent experiments



The results of the studies presented here further highlight the dependence of  $A_{2A}R$  signaling on activation of adenylylate

cyclase and the role of cAMP in  $A_{2A}R$  signaling for fibroblast collagen production, suggesting that submaximal activation of

the A<sub>2A</sub>R selectively activates PKA, favoring Col1 production but repression of Col3. However, stronger activation of A<sub>2A</sub>R activates Epac2 to stimulate both Col1 and Col3 expression. In accord with this hypothesis, it has previously been described that although cAMP affinities for Epac and PKA are similar, cAMP binds cooperatively to PKA but not to Epac, and thereby increases the responsiveness of PKA to a slight change of cAMP in the intact cell [46]. Similarly, it has been previously described that a slight intracellular cAMP increase activates cardiac fibroblast migration, which is, nonetheless, inhibited upon micromolar cAMP [25]. By highlighting the importance of intracellular cAMP levels on collagen production, our results shed some light into how a G<sub>αS</sub>-coupled receptor, the A<sub>2A</sub>R, increases both Col1 and Col3.

In summary, our work indicates that in NHDFs, adenosine mediates complex regulation of the Col1:Col3 balance, a determinant of the collagen quality in wounded versus normal skin, by fine-tuning intracellular cAMP levels. In Table 1, we have summarized our results showing that at nanomolar concentrations of the A<sub>2A</sub>R agonist (CGS<sub>low</sub>), PKA activates Col1 but represses Col3, since the latter is only increased by CGS<sub>low</sub> in the presence of PKI. In agreement, upon PKA C-α/C-β knockdown, basal Col1 and Col3 are increased, and CGS21680 further increases Col3 but not Col1. Similarly, Epac1 depletion increases Col1 and Col3, but Epac2 is needed at nanomolar and micromolar (CGS<sub>high</sub>) concentrations for Col1 expression and at micromolar for Col3 expression. Taken together, our results suggests that at nanomolar concentrations of the A<sub>2A</sub>R agonist, the PKA-mediated induction of collagen I and repression of collagen III expression increases the Col1:Col3 ratio but at higher concentrations of the A<sub>2A</sub>R agonist, and subsequent higher intracellular cAMP concentrations, the PKA inhibition of Col3 is overcome by Epac2 activation. Moreover, the observation that there is differential regulation of Col1 and Col3 by A<sub>2A</sub>R provides an attractive explanation for the observation that in normal skin, where adenosine concentration varies from 30 to 300 nM, there is a Col1 to Col3 ratio of 4:1, but in hypertrophic and immature scars, where adenosine concentration is likely to be present at higher concentrations, the ratio decreases to 2:1 [4], a decrease prevented by A<sub>2A</sub>R blockade [10].

## Methods

### Antibodies, reagents, and cell line

CGS21680 and SCH58261 were purchased from Tocris Bioscience (Ellisville, MO, USA). The PKA inhibitor (TTYADFIASGRTGRRNAIHD; PKI) was purchased from

**Table 1** Summary of the results: roles of PKA and Epac on Col1 and Col3 regulation after A<sub>2A</sub>R activation

Treatment	Col1	Col3	Pathway
CGS <sub>low</sub>	↑	≈	A <sub>2A</sub> R
CGS <sub>high</sub>	↑	↑	
PKI+CGS <sub>low</sub>	≈	↑	PKA
PKI+CGS <sub>high</sub>	≈	↑	
PKA C-α/-β siRNA+CGS	≈	↑	
Epac1/2 siRNA+CGS <sub>low</sub>	≈	≈	Epac
Epac1/2 siRNA+CGS <sub>high</sub>	≈	≈	

The A<sub>2A</sub>R agonist CGS21680 was tested at 0.1 μM (CGS<sub>low</sub>) and 1–10 μM (CGS<sub>high</sub>) concentrations, which promoted an increase (↑), a decrease (↓), or did not affect (≈) collagen production

Promega (Madison, WI, USA). Purified collagen1 and collagen3 and antibodies to collagen1 and collagen3 were purchased from SouthernBiotech (Birmingham, AL, USA). The RIPA buffer, protease inhibitor cocktail, the phosphatase inhibitor cocktail, phorbol 12-myristate 13-acetate (PMA), and the antibody to actin (H-196) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Secondary antibodies and Epac1 (sc-25632), PKA-Cβ, and PKA-Cγ antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Epac2 and PKA-Cα antibodies were from Cell Signaling Technology (Boston, MA, USA). TGF-β1 was from R&D systems (Minneapolis, MN, USA). NHDFs was purchased from Lonza (Walkersville, MD, USA).

### Stimulation and preparation of cellular extracts and Western blot

Passage 1 to 5 of 75 % confluent NHDF cells was stimulated during 24 h with the A<sub>2A</sub>R agonist CGS21680 at 0.1, 1, or 10 μM. When indicated, the A<sub>2A</sub>R antagonist SCH58261 (0.1 μM) was added 15 min or the inhibitor of PKA (PKI; 10 μg/ml) 1 h before CGS21680. For all the experiments with inhibitors/antagonists, a dose–response from 0.1 to 10 μM of CGS21680 was run in parallel. After stimulation, cells were washed with cold PBS and lysed RIPA buffer containing protease inhibitor cocktail and phosphatase inhibitor cocktail. The protein content was measured by the BCA protein assay (Thermo Fisher Scientific, Pittsburgh, PA, USA). Three micrograms of protein extract for Col1, PKA-Cα, PKA-Cβ, and PKA-Cγ and 10 μg for Col3, Epac1, and Epac2 were separated on SDS-polyacrylamide gels. Then, proteins were transferred to PVDF membranes for immunoblotting. Prior to antibody incubation, membranes were blocked in Tris-buffered saline with 0.1 % Tween 20 (TBST) plus 3 % BSA (albumin from bovine



serum, Sigma-Aldrich). Primary antibodies were incubated overnight at 4 °C at 1/500 dilution for Col1, Col3, Epac1, PKA-C $\beta$ , and PKA-C $\gamma$  while at 1/1,000 for Epac2, PKA-C $\alpha$ , and actin. Membranes were then washed with TBST, incubated with an anti-goat IgG alkaline phosphatase-conjugated secondary antibody at 1/3,000, anti-Mouse IgG alkaline phosphatase-conjugated 1/3,000, or anti-rabbit IgG alkaline phosphatase-conjugated 1/2,000 for 1 h at room temperature, and detection was performed using the ECF substrate for Western Blotting (GE Healthcare, London). Images were captured by the Typhoon Trio (GE Healthcare). Data was analyzed and quantified with Scion Image software (Scion Corporation, Frederick, MD, USA). Band quantification was first normalized to actin and then percentage was calculated to the non-stimulated control blotted in the same membrane. For collagen1, the upper band corresponding to collagen1 $\alpha$ 1 [47, 48] is represented, and calculations for collagen1 $\alpha$ 2 provided nearly identical results. Prior to Col1:Col3 ratio calculation, standard curves with purified collagen1 and collagen3 and a loading curve with cellular extracts for both types of collagen were analyzed showing that Col1 is more abundant than Col3 in NHDF (Supplemental Figure 3).

#### Quantitative RT-PCR

NHDF were serum starved for 24 h and stimulated with CGS21680 1  $\mu$ M for 24 h. Total RNA was extracted and purified using the RNeasy Mini Kit (QIAGEN, 74704, Valencia, CA, USA) according to the manufacturer's protocol. Relative quantification of gene expression was performed using real-time RT-PCR on Mx3005P Real-Time PCR System (Stratagene, Agilent Technologies, Santa Clara, CA, USA) with SYBR Green (Agilent Technologies, 600548, Santa Clara, CA, USA) according to the manufacturer's protocol. The following primers were used in real-time PCR amplification: ACTIN forward: 5-TCACCCACACTGTGCCCATC TACGA-3, reverse: 5-CAGCGGAACCGCTCATTGCCAAT GG-3; Collagen1 $\alpha$ 1 forward: 5'-TGTTTCAGCTTTGTGGAC CTCCG-3', reverse: 5'-CCGTTCTGTACGCAGGTGATTG-3'; Collagen3 $\alpha$ 1 forward: 5'-GAAGATGTCCTTGATGT GC-3', reverse: 5'-AGCCTTGCGTGTTTCGATAT-3'. mRNA abundance was determined relative to that of ACTIN.

#### cAMP measurement

Intracellular cAMP was measured with the Amersham (Arlington Heights, IL, USA) cAMP Biotrak Enzyme immunoassay system. Briefly, 75 % confluent NHDF were starved for 24 h and incubated at the indicating concentrations of CGS21680 for 20 min. cAMP levels were analyzed by using the non-acetylation EIA procedure according to the manufacturer's protocol.

#### Protein kinase A assay

The non-radioactive PepTag PKA assay (Promega, Madison, WI, USA) was used to measure PKA activity from cell lysates. The PepTag PKA assay is based on the phosphorylation of the fluorescent PKA substrate peptide, Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) (PepTag A1 peptide) which, upon phosphorylation by PKA, acquires a negative charge and can be separated from the non-phosphorylated peptide by agarose gel electrophoresis. Ninety percent confluent NHDF in 100-mm culture wells were serum starved for 24 h and stimulated for 15 min with CGS21680 (1  $\mu$ M). When indicated, the PKA inhibitor PKI (10  $\mu$ g/ml) was added 1 h before CGS21680. Positive and negative controls and spectrophotometric quantification of kinase activity following agarose solubilization were performed according to the manufacturer's protocol.

#### Rap1 activation assay

Ninety percent confluent NHDF in 100-mm culture wells were serum starved for 24 h and stimulated for 15 min with CGS21680 (1  $\mu$ M). Rap1 activation assays using a GST-tagged fusion protein corresponding to amino acids 788–884 of the human Ral-GDS-Rap binding domain bound to glutathione agarose (Ral GDS-RBD agarose) were performed using a Rap1 activation assay kit according to the manufacturer's directions (Millipore, Billerica, MA, USA).

#### RNA interference (siRNA)

Double-stranded siRNAs to Epac1 (s20360), Epac2 (s21816), the catalytic subunits PKA-C $\alpha$  (s11065), PKA-C $\beta$  (s11068), and PKA-C $\gamma$  (s11071) and negative siRNA (4390844) used as a control were purchased from Ambion (Life Technologies, Grand Island, NY, USA). Cells were transfected with siRNA (5 pmol for Epac1; 50 pmol for Epac2, PKA $\alpha$ , PKA $\beta$ , and PKA $\gamma$ ; and 25 pmol of each for the double knockdown, with the negative control at the respective concentrations), using Lipofectamine RNAiMAX (Invitrogen, Life Technologies, Grand Island, NY, USA). After 24 h, CGS21680 was added for 24 h, and cellular extracts were prepared as described above.

#### Statistical analysis

Statistical differences were determined using two-way ANOVA, repeated measures ANOVA followed by Newman–Keuls post-test, or Student's *t* test carried out using GraphPad software on a PC. The alpha nominal level was set at 0.05 in all cases. A *P* value of <0.05 was considered significant.

**Acknowledgements** This work was supported by grants from the National Institutes of Health (AR56672 and AR54897), NYU-HHC (Health and Hospitals Corporation) Clinical and Translational Science Institute (UL1RR029893), NYU Cancer Institute Center Support Grant, and NIH/National Cancer Institute (5 P30CA16087-31).

**Conflicts of interest** AM and BNC have filed a patent on use of adenosine A2AR agonists to prevent prosthesis loosening (pending). MP-A does not have any disclosures. BNC holds patents numbers 5,932,558; 6,020,321; 6,555,545; 7,795,427; adenosine A1R and A2BR antagonists to treat fatty liver (pending); and adenosine A2AR agonists to prevent prosthesis loosening (pending). BNC is a consultant for Bristol-Myers Squibb, Novartis, CanFite Biopharmaceuticals, Cypress Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc., Savient, Gismo Therapeutics, Antares Pharmaceutical, Medivector, King Pharmaceutical, Celizome, Tap Pharmaceuticals, Prometheus Laboratories, Sepracor, Amgen, Combinatorx, Kyowa Hakka, Hoffman-LaRoche, and Avidimer Therapeutics. BNC has stock in CanFite Biopharmaceuticals.

## References

- Williams JC (1980) Adenine nucleotide degradation by the obligate intracellular bacterium *Rickettsia typhi*. *Infect Immun* 28(1):74–81
- Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. *Trends Immunol* 25(1):33–39
- Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. *Nature* 414(6866):916–920
- Stadelmann WK, Digenis AG, Tobin GR (1998) Physiology and healing dynamics of chronic cutaneous wounds. *Am J Surg* 176(2A Suppl):26S–38S
- Victor-Vega C, Desai A, Montesinos MC, Cronstein BN (2002) Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel). *Inflammation* 26(1):19–24
- Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN (2002) Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. *Am J Pathol* 160(6):2009–2018
- Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D, Reibman J, Li M, Jiang CK, Hirschhorn R, Recht PA, Ostad E, Levin RI, Cronstein BN (1997) Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. *J Exp Med* 186(9):1615–1620
- Katebi M, Fernandez P, Chan ES, Cronstein BN (2008) Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis. *Inflammation* 31(5):299–303
- Lazzerini PE, Natale M, Giancetti E, Capocchi PL, Montilli C, Zimbone S, Castrichini M, Balistreri E, Ricci G, Selvi E, Garcia-Gonzalez E, Galeazzi M, Laghi-Pasini F (2012) Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. *J Mol Med (Berl)* 90(3):331–342
- Perez-Aso M, Chiriboga L, Cronstein BN (2012) Pharmacological blockade of adenosine A2A receptors diminishes scarring. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology* 26(10):4254–4263. doi:10.1096/fj.12-209627
- Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, Reiss AB, Pillinger MH, Chen JF, Schwarzschild MA, Friedman SL, Cronstein BN (2006) Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. *Br J Pharmacol* 148(8):1144–1155. doi:10.1038/sj.bjp.0706812
- Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB, Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN (2006) Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. *Arthritis and Rheumatism* 54(8):2632–2642. doi:10.1002/art.21974
- Kaul A, Chandra M, Misra MK (2006) Adenosine deaminase in ischemia reperfusion injury in patients with myocardial infarction. *Journal of Enzyme Inhibition and Medicinal Chemistry* 21(5):543–546. doi:10.1080/14756360600774520
- Chan ES, Liu H, Fernandez P, Luna A, Perez-Aso M, Bujor AM, Trojanowska M, Cronstein BN (2013) Adenosine A2A receptors promote collagen production by a Fli1- and CTGF-mediated mechanism. *Arthritis Res Ther* 15(3):R58
- Che J, Chan ES, Cronstein BN (2007) Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway. *Mol Pharmacol* 72(6):1626–1636. doi:10.1124/mol.107.038760
- Lazarova T, Brewin KA, Stoeber K, Robinson CR (2004) Characterization of peptides corresponding to the seven transmembrane domains of human adenosine A2a receptor. *Biochemistry* 43(40):12945–12954
- Thevenin D, Roberts MF, Lazarova T, Robinson CR (2005) Identifying interactions between transmembrane helices from the adenosine A2A receptor. *Biochemistry* 44(49):16239–16245
- Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from antitumor T cells. *Proc Natl Acad Sci USA* 103(35):13132–13137
- Bingham TC, Fisher EA, Parathath S, Reiss AB, Chan ES, Cronstein BN (2010) A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux. *J Leukoc Biol* 87(4):683–690
- Kreckler LM, Gizewski E, Wan TC, Auchampach JA (2009) Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. *J Pharmacol Exp Ther* 331(3):1051–1061
- Seidel MG, Klinger M, Freissmuth M, Holler C (1999) Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway. *J Biol Chem* 274(36):25833–25841
- Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W (2000) Structure and function of adenosine receptors and their genes. *Naunyn Schmiedebergs Arch Pharmacol* 362(4–5):364–374
- Schulte G, Fredholm BB (2003) Signalling from adenosine receptors to mitogen-activated protein kinases. *Cell Signal* 15(9):813–827
- Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D, Aroonsakool N (2012) cAMP and Epac in the regulation of tissue fibrosis. *Br J Pharmacol* 166(2):447–456
- Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, Insel PA (2008) The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. *Proc Natl Acad Sci USA* 105(17):6386–6391
- Ji Z, Mei FC, Miller AL, Thompson EB, Cheng X (2008) Protein kinase A (PKA) isoform RIIbeta mediates the synergistic killing effect of cAMP and glucocorticoid in acute lymphoblastic leukemia cells. *J Biol Chem* 283(32):21920–21925

27. Jimenez SA, Hitraya E, Varga J (1996) Pathogenesis of scleroderma. *Collagen Rheum Dis Clin North Am* 22(4):647–674
28. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* 53(4):527–552
29. Fernandez P, Trzaska S, Wilder T, Chiriboga L, Blackburn MR, Cronstein BN, Chan ES (2008) Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. *Am J Pathol* 172(6):1675–1682. doi:10.2353/ajpath.2008.070952
30. Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. *N Engl J Med* 364(7):656–665. doi:10.1056/NEJMr0910283
31. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK (2008) Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. *Circulation* 118(2):166–175. doi:10.1161/CIRCULATIONAHA.107.758516
32. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK (2007) Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. *Circulation* 115(12):1581–1590. doi:10.1161/CIRCULATIONAHA.106.669697
33. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP (2002) Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. *J Clin Invest* 110(7):993–1002. doi:10.1172/JCI15337
34. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. *J Clin Invest* 117(12):3810–3820. doi:10.1172/JCI30487
35. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP (2006) HIF-dependent induction of adenosine A2B receptor in hypoxia. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology* 20(13):2242–2250. doi:10.1096/fj.06-6419.com
36. Grenz A, Bauerle JD, Dalton JH, Ridyad D, Badulak A, Tak E, McNamee EN, Clambey E, Moldovan R, Reyes G, Klawitter J, Ambler K, Magee K, Christians U, Brodsky KS, Ravid K, Choi DS, Wen J, Lukashev D, Blackburn MR, Osswald H, Coe IR, Nurnberg B, Haase VH, Xia Y, Sitkovsky M, Eltzschig HK (2012) Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. *J Clin Invest* 122(2):693–710. doi:10.1172/JCI60214
37. Koeppen M, Eckle T, Eltzschig HK (2011) Interplay of hypoxia and A2B adenosine receptors in tissue protection. *Adv Pharmacol* 61:145–186. doi:10.1016/B978-0-12-385526-8.00006-0
38. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC, Stenmark KR, Colgan SP, Eltzschig HK (2012) Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. *Proc Natl Acad Sci U S A* 109(41):E2784–E2793. doi:10.1073/pnas.1202366109
39. Milne GR, Palmer TM (2011) Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. *ScientificWorldJournal* 11:320–339
40. Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M (2009) A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. *J Immunol* 183(9):5487–5493
41. Yano N, Suzuki D, Endoh M, Zhao TC, Padbury JF, Tseng YT (2007) A novel phosphoinositide 3-kinase-dependent pathway for angiotensin II/AT-1 receptor-mediated induction of collagen synthesis in MES-13 mesangial cells. *J Biol Chem* 282(26):18819–18830
42. Pidoux G, Tasken K (2010) Specificity and spatial dynamics of protein kinase A signaling organized by A-kinase-anchoring proteins. *J Mol Endocrinol* 44(5):271–284
43. Skalhegg BS, Tasken K (2000) Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. *Front Biosci* 5(5):D678–D693
44. Insel PA, Bourne HR, Coffino P, Tomkins GM (1975) Cyclic AMP-dependent protein kinase: pivotal role in regulation of enzyme induction and growth. *Science* 190(4217):896–898
45. Breckler M, Berthouze M, Laurent AC, Crozatier B, Morel E, Lezoualc'h F (2011) Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. *Cell Signal* 23(8):1257–1266
46. Dao KK, Teigen K, Kopperud R, Hodneland E, Schwede F, Christensen AE, Martinez A, Doskeland SO (2006) Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. *J Biol Chem* 281(30):21500–21511
47. Butkowski RJ (1982) Estimation of the size of collagenous proteins by electrophoresis and gel chromatography. In: Cunningham LW, Frederickson DW (eds) *Methods in enzymology*, vol 82. Academic Press, New York, pp 410–423
48. Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD (2007) SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. *J Biol Chem* 282(30):22062–22071